Trial Profile
A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2014
Price :
$35
*
At a glance
- Drugs JSM 6427 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Jerini Ophthalmic
- 15 May 2014 New trial record